Cantor Fitzgerald Estimates MLTX FY2026 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for MoonLake Immunotherapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($3.78) per share for the year. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.63) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.13. During the same period in the previous year, the company posted ($0.22) EPS.

Several other analysts have also issued reports on MLTX. Wedbush reaffirmed an "outperform" rating and issued a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price objective for the company in a report on Monday, May 19th. The Goldman Sachs Group reduced their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $67.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 3rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, MoonLake Immunotherapeutics presently has an average rating of "Buy" and an average target price of $78.71.

MoonLake Immunotherapeutics Stock Up 0.4%

Shares of MoonLake Immunotherapeutics stock traded up $0.19 during trading on Tuesday, hitting $44.21. 316,243 shares of the stock traded hands, compared to its average volume of 384,031. The stock has a market cap of $2.83 billion, a price-to-earnings ratio of -34.27 and a beta of 1.23. MoonLake Immunotherapeutics has a 52 week low of $31.42 and a 52 week high of $58.26. The firm's fifty day moving average is $40.03 and its 200-day moving average is $43.65.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MLTX. FMR LLC raised its holdings in MoonLake Immunotherapeutics by 28.1% during the 4th quarter. FMR LLC now owns 6,341,391 shares of the company's stock valued at $343,386,000 after buying an additional 1,391,167 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of MoonLake Immunotherapeutics by 12.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company's stock valued at $181,059,000 after acquiring an additional 363,394 shares during the period. Paradigm Biocapital Advisors LP increased its position in shares of MoonLake Immunotherapeutics by 90.3% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company's stock valued at $95,965,000 after acquiring an additional 840,731 shares during the period. Westfield Capital Management Co. LP raised its stake in shares of MoonLake Immunotherapeutics by 9.4% during the first quarter. Westfield Capital Management Co. LP now owns 1,434,770 shares of the company's stock valued at $56,056,000 after acquiring an additional 123,151 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of MoonLake Immunotherapeutics by 13.2% during the fourth quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company's stock worth $69,315,000 after purchasing an additional 149,724 shares during the period. Institutional investors own 93.85% of the company's stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.